Choice of first line systemic treatment in pancreatic cancer among national experts.

Details

Serval ID
serval:BIB_C847DAC2A00B
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Choice of first line systemic treatment in pancreatic cancer among national experts.
Journal
Pancreatology
Author(s)
Glatzer M., Horber D., Montemurro M., Winterhalder R., Inauen R., Berger M.D., Pestalozzi B., Pederiva S., Pless M., Putora P.M.
ISSN
1424-3911 (Electronic)
ISSN-L
1424-3903
Publication state
Published
Issued date
06/2020
Peer-reviewed
Oui
Volume
20
Number
4
Pages
686-690
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Treatment options for patients with metastatic pancreatic cancer depend on various factors, including performance status, tumor burden and patient preferences. Metastatic pancreatic cancer is incurable and many systemic treatment options have been investigated over the past decades. This analysis of patterns of practice was performed to identify decision criteria and their impact on the choice of first-line management of metastatic pancreatic cancer.
Members of the Swiss Group for Clinical Cancer Research (SAKK) Gastrointestinal Cancer Group were contacted and agreed to participate in this analysis. Decision trees for the first line treatment of metastatic pancreatic cancer from 9 centers in Switzerland were collected and analyzed based on the objective consensus methodology to identify consensus and discrepancies in clinical decision-making.
The final treatment algorithms included 3 decision criteria (comorbidities, performance status and age) and 5 treatment options: FOLFIRINOX, FOLFOX, gemcitabine + nab-paclitaxel, gemcitabine mono and best supportive care.
We identified multiple decision criteria relevant to all participating centers. We found consensus for the treatment of young (age below 65) patients with good performance status with FOLFIRINOX. For patients with increasing age and reducing performance status there was a decreasing trend to use gemcitabine + nab-paclitaxel. Gemcitabine monotherapy was typically offered to patients in the presence of comorbidities. For patients with ECOG 3-4, most of the experts recommended BSC.
Keywords
Antineoplastic Agents/administration & dosage, Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Clinical Decision-Making, Humans, Pancreatic Neoplasms/drug therapy, Pancreatic Neoplasms/epidemiology, Pancreatic Neoplasms/pathology, Switzerland/epidemiology, Decision criteria, FOLFIRINOX, Nab-paclitaxel, Pancreatic cancer, Treatment algorithm, decision-making
Pubmed
Web of science
Create date
25/04/2020 19:00
Last modification date
05/05/2021 5:36
Usage data